• 1
    Baggott JE, Morgan SL, Ha TS, Vaughn WH, Hine RJ: Inhibition of folate-dependent enzymes by non-steroidal antiinflammatory drugs. Biochem J 282: 197202, 1992
  • 2
    Morgan SL, Baggott JE, Altz-Smith M: Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy. Arthritis Rheum 30: 13481356, 1987
  • 3
    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33: 918, 1990
  • 4
    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Alarcón GS, Krumdieck CL, Koopman WJ: 5 mg or 50 mg/week of folic acid supplementation does not alter the efficacy of methotrexate treated rheumatoid arthritis patients (abstract) Arthritis Rheum 35 (suppl 5): R18, 1992
  • 5
    Baum CL, Selhub J, Rosenberg IH: Antifolate actions of sulfasalazine on intact lymphocytes. J Lab Clin Med 97: 779784, 1981
  • 6
    Alarcón GS, Tracy IC, Blackburn WD Jr: Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32: 671676, 1989
  • 7
    Pullar T, Capell HA: Sulphasalazine: a “new” antirheumatic drug. Br J Rheumatol 23: 2634, 1984
  • 8
    Morgan SL, Baggott JE: Role of dietary folate and oral folate supplements in the prevention of drug toxicity during antifolate therapy for nonneoplastic disease, Micronutrients in Health and in Disease Prevention. Edited by A Bendich, CE Butterworth. New York, Marcel Dekker, 1991
  • 9
    Liddle BJ, Mardsen JR: Drug interactions with methotrexate (letter). Br J Dermatol 120: 582583, 1989
  • 10
    Chatham WW: Methotrexate associated rheumatoid nodulosis—improvement with addition of sulfasalazine (abstract) Arthritis Rheum 35 (suppl 5): R15, 1992